POTP

(redirected from Point Therapeutics)
AcronymDefinition
POTPPart Of The Problem (World of Warcraft guild)
POTPProfessor of the Practice (Carnegie-Mellon University School of Computer Science; Pittsburgh, PA)
POTPPieces of the Puzzle (Harry Potter fanfiction)
POTPPower of the Paw
POTPPut Out to Pasture
POTPParty on the Potomac (boating club)
POTPPoint Therapeutics (stock symbol)
POTPPop on the Pop (website)
POTPPacket Optical Transport Platform
POTPPower of the Pen
POTPPicnic on the Pyre (band)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
* Turning Point Therapeutics, Inc.(NASDAQ: TPTX) dropped 5.5% to close at $48.20 after the company reported a common stock offering of 4.5 million shares.
Turning Point Therapeutics announced updated interim data from the Phase 1 portion of its ongoing Phase 1/2 TRIDENT-1 clinical study of lead drug candidate repotrectinib in patients with ROS1-positive non-small cell lung cancer,NSCLC,and TRK-positive patients with advanced solid tumors.
ENPNewswire-August 7, 2019--Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results
M2 PHARMA-April 22, 2019-Turning Point Therapeutics Prices US Initial Public Offering
* Turning Point Therapeutics, Inc.(NASDAQ: TPTX) dropped 10% to $45.90 after the company reported a common stock offering of 4.5 million shares.
ENPNewswire-August 1, 2019--Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors
Turning Point Therapeutics announced initiation of a Phase 1 clinical study of patients with advanced solid tumors harboring genetic alterations in MET.
ENPNewswire-August 1, 2019--Turning Point Therapeutics' CEO to Present at Canaccord Genuity 39th Annual Growth Conference
Turning Point Therapeutics announced initiation of the registrational Phase 2 portion of its TRIDENT-1 clinical study of patients with ROS1+ advanced non-small cell lung cancer and TRK+ advanced solid tumors.
Turning Point Therapeutics announced updated interim data from its ongoing Phase 1/2 TRIDENT-1 clinical study of lead drug candidate repotrectinib in ROS1-positive non-small cell lung cancer, or NSCLC, patients.
Turning Point Therapeutics announced clearance by the FDA of its investigational new drug, or IND, application for TPX-0022, a therapy targeting solid tumors by inhibiting the MET, CSF1R and SRC kinases.